Deirdre Gillespie
Chief Executive Officer at IRAD Oncology, Inc.
Deirdre Gillespie active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IRAD Oncology, Inc. | Chief Executive Officer | 31/12/2012 | - |
Career history of Deirdre Gillespie
Former positions of Deirdre Gillespie
| Companies | Position | Start | End |
|---|---|---|---|
Apricus Biosciences, Inc.
 Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Director/Board Member | 22/06/2010 | 04/04/2016 |
| Independent Dir/Board Member | 21/06/2010 | 04/04/2016 | |
| LA JOLLA PHARMACEUTICAL COMPANY | Director/Board Member | 27/07/2011 | 18/01/2012 |
| Chief Executive Officer | 13/03/2006 | 18/01/2012 | |
| President | 13/03/2006 | 18/01/2012 | |
Oxxon Therapeutics, Inc.
 Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | President | 31/12/2000 | 31/12/2004 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Operating Officer | 31/12/1997 | 31/12/2000 |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Sales & Marketing | 31/12/1990 | 31/12/1995 |
Virttu Biologics Ltd.
 Virttu Biologics Ltd. Pharmaceuticals: OtherHealth Technology Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom. | Chief Executive Officer | - | - |
Training of Deirdre Gillespie
| University of London | Doctorate Degree |
| London Business School | Masters Business Admin |
Statistics
International
| United States | 6 |
| United Kingdom | 5 |
Operational
| Chief Executive Officer | 3 |
| President | 2 |
| Director/Board Member | 2 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 7 |
|---|---|
Oxxon Therapeutics, Inc.
Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Health Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
| IRAD Oncology, Inc. | |
Virttu Biologics Ltd.
Virttu Biologics Ltd. Pharmaceuticals: OtherHealth Technology Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Deirdre Gillespie
- Experience
